Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Syntara Limited (UUD) Stock Price & Analysis

UUD Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 21.09M
Enterprise Value
CHF 21.58M
Total Cash (Recent Filing)
CHF 13.56M
Total Debt (Recent Filing)
CHF 0
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The absence of debt and sizeable equity base reduce solvency and refinancing pressure compared with earlier periods of higher leverage. This gives Syntara greater balance-sheet flexibility to support clinical development and absorb operating volatility over the next several quarters.

Specialised Drug Platform

A focused amine oxidase platform gives Syntara a defined scientific foundation across fibrosis and oncology rather than an undifferentiated drug pipeline. If development advances, platform reuse across indications could support broader clinical opportunities from shared expertise.

Historical Gross Profitability

The historical gross margin indicates that Syntara’s underlying offerings generated positive gross economics when revenue was present. Although current revenue is absent, this prior evidence provides some support that eventual commercialisation could produce value before operating costs are considered.

Bears Say

No Recent Revenue

The absence of reported revenue means Syntara currently lacks an established commercial earnings stream to fund operations or validate market adoption. This leaves future financial performance dependent on successful development and eventual commercialisation rather than recurring business activity.

Persistent Net Losses

Continuing and worsening net losses show that the business is not yet converting its development activity into sustainable profitability. Persistent operating deficits can erode the equity base over time and increase the importance of successful pipeline execution for long-term financial viability.

Ongoing Cash Burn

Negative operating and free cash flow demonstrate that current activities consume cash rather than self-fund growth. Even with low debt, sustained burn can reduce liquidity and require additional funding, making development continuity increasingly dependent on capital access.

Syntara Limited News

UUD FAQ

What is Syntara Limited’s market cap?
Syntara Limited’s market cap is CHF21.09M.
When is Syntara Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Syntara Limited’s earnings last quarter?
Syntara Limited released its earnings results on Sep 02, 2026. The company reported -CHF0.001 earnings per share for the quarter.
Is Syntara Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Syntara Limited pay dividends?
Syntara Limited does not currently pay dividends.
What is Syntara Limited’s EPS estimate?
Syntara Limited’s EPS estimate for its next earnings report is not yet available.
What happened to Syntara Limited’s price movement after its last earnings report?
Syntara Limited reported an EPS of -CHF0.001 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Syntara Limited?
Currently, no hedge funds are holding shares in CH:UUD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology